Detalles de la búsqueda
1.
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
J Eur Acad Dermatol Venereol
; 37(5): 1017-1027, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36695061
2.
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
Dermatol Ther
; 35(6): e15488, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35384168
3.
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Dermatol Ther
; 35(1): e15166, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34676662
4.
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.
Allergy
; 76(6): 1813-1824, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34152613
5.
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.
Acta Derm Venereol
; 101(3): adv00422, 2021 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-33269404
6.
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
BMC Health Serv Res
; 21(1): 924, 2021 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34488749
7.
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature.
Dermatol Ther
; 32(3): e12899, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30969010
8.
Successful treatment of psoriatic crumbly nails with ustekinumab.
Dermatol Ther
; 32(3): e12914, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30968520
9.
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients.
Dermatology
; 232(6): 648-654, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-28152541
10.
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
Dermatology
; 232(2): 230-6, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26678060
11.
What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.
Dermatology
; 229(4): 324-32, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25402662
12.
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.
Drug Dev Res
; 75 Suppl 1: S11-4, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25381966
13.
Successful long-term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series.
Skin Health Dis
; 4(1): e289, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38312241
14.
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks.
J Clin Med
; 13(3)2024 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38337572
15.
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden.
Expert Opin Biol Ther
; 24(3): 133-138, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38444107
16.
Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report.
Skin Health Dis
; 4(3): e354, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38846697
17.
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study.
J Clin Med
; 13(7)2024 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38610641
18.
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab.
Dermatitis
; 2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38669092
19.
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
Expert Opin Pharmacother
; 24(9): 981-988, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37147879
20.
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.
Expert Opin Biol Ther
; 23(4): 371-381, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36971507